Advanced

Comparing Health Outcomes and Costs of General Vaccination with Pneumococcal Conjugate Vaccines in Sweden: A Markov Model

By, Asa; Sobocki, Patrik; Forsgren, Arne LU and Silfverdal, Sven-Arne (2012) In Clinical Therapeutics 34(1). p.177-189
Abstract
Background: Two new pneumococcal conjugate vaccines were licensed to immunize infants and young children against pneumococcal disease. Objectives: The objective of this study was to estimate the expected health benefits, costs, and incremental cost-effectiveness of routine vaccination with the 10-valent pneumococcal nontypeable hemophilus influenza protein-D conjugate vaccine (PHiD-CV) compared with the 13-valent pneumococcal conjugate vaccine (PCV13) in Sweden. Methods: A Markov cohort model was used to estimate the effect of vaccination at vaccine steady state, taking a societal perspective and using a 2+1 vaccination schedule. Price parity was assumed between the vaccines. Outcomes were measured by reduction in disease burden, costs,... (More)
Background: Two new pneumococcal conjugate vaccines were licensed to immunize infants and young children against pneumococcal disease. Objectives: The objective of this study was to estimate the expected health benefits, costs, and incremental cost-effectiveness of routine vaccination with the 10-valent pneumococcal nontypeable hemophilus influenza protein-D conjugate vaccine (PHiD-CV) compared with the 13-valent pneumococcal conjugate vaccine (PCV13) in Sweden. Methods: A Markov cohort model was used to estimate the effect of vaccination at vaccine steady state, taking a societal perspective and using a 2+1 vaccination schedule. Price parity was assumed between the vaccines. Outcomes were measured by reduction in disease burden, costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio. Results: The results predicted that PCV13 would prevent 3 additional cases of invasive pneumococcal disease and 34 additional cases of pneumonia, whereas PHiD-CV would avoid 3 additional cases of mastoiditis, 1010 tube insertions, and 10,420 cases of ambulatory acute otitis media compared with PCV13. By combining morbidity and mortality benefits of all clinical outcomes, PHiD-CV would generate 45.3 additional QALYs compared with PCV13 and generate savings of an estimated 62 million Swedish kronors. Conclusion: The present study predicted lower costs and better health outcome (QALYs) gained by introducing PHiD-CV compared with PCV13 in routine vaccination. Our results indicated that PHiD-CV is cost-effective compared with PCV13 in Sweden. (Clin Ther. 2012;34:177-189) (C) 2012 Elsevier HS Journals, Inc. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cost-effectiveness analysis, costs, health outcomes, PHiD-CV, PCV13, pneumococcal disease, vaccine
in
Clinical Therapeutics
volume
34
issue
1
pages
177 - 189
publisher
Excerpta Medica
external identifiers
  • wos:000300337300015
  • scopus:84856134094
ISSN
0149-2918
DOI
10.1016/j.clinthera.2011.12.007
language
English
LU publication?
yes
id
116b3c1c-f4cd-4357-9c34-a3d129cda02e (old id 2403255)
date added to LUP
2012-04-02 09:28:09
date last changed
2017-09-03 03:27:32
@article{116b3c1c-f4cd-4357-9c34-a3d129cda02e,
  abstract     = {Background: Two new pneumococcal conjugate vaccines were licensed to immunize infants and young children against pneumococcal disease. Objectives: The objective of this study was to estimate the expected health benefits, costs, and incremental cost-effectiveness of routine vaccination with the 10-valent pneumococcal nontypeable hemophilus influenza protein-D conjugate vaccine (PHiD-CV) compared with the 13-valent pneumococcal conjugate vaccine (PCV13) in Sweden. Methods: A Markov cohort model was used to estimate the effect of vaccination at vaccine steady state, taking a societal perspective and using a 2+1 vaccination schedule. Price parity was assumed between the vaccines. Outcomes were measured by reduction in disease burden, costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio. Results: The results predicted that PCV13 would prevent 3 additional cases of invasive pneumococcal disease and 34 additional cases of pneumonia, whereas PHiD-CV would avoid 3 additional cases of mastoiditis, 1010 tube insertions, and 10,420 cases of ambulatory acute otitis media compared with PCV13. By combining morbidity and mortality benefits of all clinical outcomes, PHiD-CV would generate 45.3 additional QALYs compared with PCV13 and generate savings of an estimated 62 million Swedish kronors. Conclusion: The present study predicted lower costs and better health outcome (QALYs) gained by introducing PHiD-CV compared with PCV13 in routine vaccination. Our results indicated that PHiD-CV is cost-effective compared with PCV13 in Sweden. (Clin Ther. 2012;34:177-189) (C) 2012 Elsevier HS Journals, Inc. All rights reserved.},
  author       = {By, Asa and Sobocki, Patrik and Forsgren, Arne and Silfverdal, Sven-Arne},
  issn         = {0149-2918},
  keyword      = {cost-effectiveness analysis,costs,health outcomes,PHiD-CV,PCV13,pneumococcal disease,vaccine},
  language     = {eng},
  number       = {1},
  pages        = {177--189},
  publisher    = {Excerpta Medica},
  series       = {Clinical Therapeutics},
  title        = {Comparing Health Outcomes and Costs of General Vaccination with Pneumococcal Conjugate Vaccines in Sweden: A Markov Model},
  url          = {http://dx.doi.org/10.1016/j.clinthera.2011.12.007},
  volume       = {34},
  year         = {2012},
}